UNLABELLED: Primary sclerosing cholangitis (PSC) is an incurable cholangiopathy of unknown etiopathogenesis. Here we tested the hypothesis that cholangiocyte senescence is a pathophysiologically important phenotype in PSC. We assessed markers of cellular senescence and senescence-associated secretory phenotype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals by fluorescent in situ hybridization (FISH) and immunofluorescence microscopy (IFM). We tested whether endogenous and exogenous biliary constituents affect senescence and SASP in cultured human cholangiocytes. We determined in coculture whether senescent cholangiocytes induce senescence in bystander cholangiocytes. Finally, we explored signaling mechanisms involved in cholangiocyte senescence and SASP. In vivo, PSC cholangiocytes expressed significantly more senescence-associated p16(INK4a) and γH2A.x compared to the other three conditions; expression of profibroinflammatory SASP components (i.e., IL-6, IL-8, CCL2, PAI-1) was also highest in PSC cholangiocytes. In vitro, several biologically relevant endogenous (e.g., cholestane 3,5,6 oxysterol) and exogenous (e.g., lipopolysaccharide) molecules normally present in bile induced cholangiocyte senescence and SASP. Furthermore, experimentally induced senescent human cholangiocytes caused senescence in bystander cholangiocytes. N-Ras, a known inducer of senescence, was increased in PSC cholangiocytes and in experimentally induced senescent cultured cholangiocytes; inhibition of Ras abrogated experimentally induced senescence and SASP. CONCLUSION: Cholangiocyte senescence induced by biliary constituents by way of N-Ras activation is an important pathogenic mechanism in PSC. Pharmacologic inhibition of N-Ras with a resultant reduction in cholangiocyte senescence and SASP is a new therapeutic approach for PSC.
UNLABELLED: Primary sclerosing cholangitis (PSC) is an incurable cholangiopathy of unknown etiopathogenesis. Here we tested the hypothesis that cholangiocyte senescence is a pathophysiologically important phenotype in PSC. We assessed markers of cellular senescence and senescence-associated secretory phenotype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals by fluorescent in situ hybridization (FISH) and immunofluorescence microscopy (IFM). We tested whether endogenous and exogenous biliary constituents affect senescence and SASP in cultured human cholangiocytes. We determined in coculture whether senescent cholangiocytes induce senescence in bystander cholangiocytes. Finally, we explored signaling mechanisms involved in cholangiocyte senescence and SASP. In vivo, PSC cholangiocytes expressed significantly more senescence-associated p16(INK4a) and γH2A.x compared to the other three conditions; expression of profibroinflammatory SASP components (i.e., IL-6, IL-8, CCL2, PAI-1) was also highest in PSC cholangiocytes. In vitro, several biologically relevant endogenous (e.g., cholestane 3,5,6 oxysterol) and exogenous (e.g., lipopolysaccharide) molecules normally present in bile induced cholangiocyte senescence and SASP. Furthermore, experimentally induced senescent human cholangiocytes caused senescence in bystander cholangiocytes. N-Ras, a known inducer of senescence, was increased in PSC cholangiocytes and in experimentally induced senescent cultured cholangiocytes; inhibition of Ras abrogated experimentally induced senescence and SASP. CONCLUSION: Cholangiocyte senescence induced by biliary constituents by way of N-Ras activation is an important pathogenic mechanism in PSC. Pharmacologic inhibition of N-Ras with a resultant reduction in cholangiocyte senescence and SASP is a new therapeutic approach for PSC.
Authors: Consuelo M López de Padilla; Abbe N Vallejo; Kelly T McNallan; Richard Vehe; Stephen A Smith; Allan B Dietz; Stanimir Vuk-Pavlovic; Ann M Reed Journal: Arthritis Rheum Date: 2007-05
Authors: Mykyta V Sokolov; Lubomir B Smilenov; Eric J Hall; Igor G Panyutin; William M Bonner; Olga A Sedelnikova Journal: Oncogene Date: 2005-11-10 Impact factor: 9.867
Authors: G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith Journal: Proc Natl Acad Sci U S A Date: 1995-09-26 Impact factor: 11.205
Authors: Tobias Mueller; Claudia Beutler; Almudena Hurtado Picó; Oren Shibolet; Daniel S Pratt; Andreas Pascher; Peter Neuhaus; Bertram Wiedenmann; Thomas Berg; Daniel K Podolsky Journal: Liver Int Date: 2011-09-15 Impact factor: 5.828
Authors: Edward Alabraba; Peter Nightingale; Bridget Gunson; Stefan Hubscher; Simon Olliff; Darius Mirza; James Neuberger Journal: Liver Transpl Date: 2009-03 Impact factor: 5.799
Authors: Jean-Philippe Coppé; Christopher K Patil; Francis Rodier; Yu Sun; Denise P Muñoz; Joshua Goldstein; Peter S Nelson; Pierre-Yves Desprez; Judith Campisi Journal: PLoS Biol Date: 2008-12-02 Impact factor: 8.029
Authors: James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso Journal: Hepatology Date: 2015-08-10 Impact factor: 17.425
Authors: Angela C Cheung; Maria J Lorenzo Pisarello; Nicholas F LaRusso Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-07-15 Impact factor: 5.187
Authors: Anja Moncsek; Mohammed S Al-Suraih; Christy E Trussoni; Steven P O'Hara; Patrick L Splinter; Camille Zuber; Eleonora Patsenker; Piero V Valli; Christian D Fingas; Achim Weber; Yi Zhu; Tamar Tchkonia; James L Kirkland; Gregory J Gores; Beat Müllhaupt; Nicholas F LaRusso; Joachim C Mertens Journal: Hepatology Date: 2017-11-29 Impact factor: 17.425
Authors: James L Kirkland; Tamara Tchkonia; Yi Zhu; Laura J Niedernhofer; Paul D Robbins Journal: J Am Geriatr Soc Date: 2017-09-04 Impact factor: 5.562